- Home
- OCGN vs RCEL Comparison
OCGN vs RCEL Comparison
Compare OCGN & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCGN
- RCEL
- Stock Information
- Founded
- OCGN 2013
- RCEL N/A
- Country
- OCGN United States
- RCEL United States
- Employees
- OCGN N/A
- RCEL N/A
- Industry
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- RCEL Medical/Dental Instruments
- Sector
- OCGN Health Care
- RCEL Health Care
- Exchange
- OCGN Nasdaq
- RCEL Nasdaq
- Market Cap
- OCGN 189.6M
- RCEL 227.5M
- IPO Year
- OCGN N/A
- RCEL N/A
- Fundamental
- Price
- OCGN $0.68
- RCEL $9.21
- Analyst Decision
- OCGN Strong Buy
- RCEL Strong Buy
- Analyst Count
- OCGN 3
- RCEL 4
- Target Price
- OCGN $6.33
- RCEL $17.25
- AVG Volume (30 Days)
- OCGN 4.3M
- RCEL 201.7K
- Earning Date
- OCGN 05-13-2025
- RCEL 05-08-2025
- Dividend Yield
- OCGN N/A
- RCEL N/A
- EPS Growth
- OCGN N/A
- RCEL N/A
- EPS
- OCGN N/A
- RCEL N/A
- Revenue
- OCGN $4,054,999.00
- RCEL $64,251,000.00
- Revenue This Year
- OCGN N/A
- RCEL $62.33
- Revenue Next Year
- OCGN N/A
- RCEL $30.59
- P/E Ratio
- OCGN N/A
- RCEL N/A
- Revenue Growth
- OCGN N/A
- RCEL 28.14
- 52 Week Low
- OCGN $0.52
- RCEL $6.90
- 52 Week High
- OCGN $2.06
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- OCGN 51.84
- RCEL 56.76
- Support Level
- OCGN $0.64
- RCEL $8.15
- Resistance Level
- OCGN $0.74
- RCEL $9.36
- Average True Range (ATR)
- OCGN 0.07
- RCEL 0.67
- MACD
- OCGN 0.00
- RCEL 0.15
- Stochastic Oscillator
- OCGN 54.50
- RCEL 93.90
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.